Asthma and COPD patients are highly satisfied with the handling and inhalation from the new generation soft mist inhaler
Munich/Germany, 06 September 2006 - The results of an observational study presented today at the 16th Annual Congress of the European Respiratory Society in Munich, Germany show that patients with asthma and chronic obstructive pulmonary disease (COPD) are highly satisfied with the novel RespimatŪ Soft Mist Inhaler (SMI) from Boehringer Ingelheim.
In a 12 week observational cohort study in respiratory specialist practices in Germany, the handling, including device assembly, inhalation satisfaction and technique were assessed with a clinical questionnaire. 2006 patients from 695 centres in Germany were interviewed after 4, 8 and 12 weeks of 2-4 times daily administration of ipratropium bromide/fenoterol 20/50 μg in the RespimatŪ Soft Mist Inhaler (BDR). Most patients (66%) received treatment with the Soft Mist Inhaler for the first time.
After 4 weeks, feedback from both physicians and patients was very positive. 79% of patients and 87% of physicians were very satisfied or satisfied with the ease of the set-up for use of the Soft Mist Inhaler. Reactions to the soft mist inhalation were even more positive: 92% of patients and 97% of physicians were very satisfied or satisfied. The rating for the inhalation technique was also high: 86% of patients and 91% of physicians were very satisfied or satisfied. The ratings improved further over time.
Overall, most patients (74%) and physicians (75%) rated the treatment of ipratropium bromide/fenoterol from the Soft Mist Inhaler as better or much better than their previous treatment.
Notes to the Editor
Boehringer Ingelheimīs RespimatŪ Soft Mist Inhaler
Boehringer Ingelheimīs RespimatŪ Soft Mist Inhaler is a propellant-free, novel inhaler that generates a slow-moving, long-lasting cloud (the Soft Mist ) with a high fine particle fraction (less than 5.8 μm). The Soft Mist travels more slowly and lasts much longer than aerosol clouds from traditional devices. Scintigraphic studies have shown that these properties improve the deposition of drug in the lungs and produce less deposition in mouth and throat than the pressurised metered dose inhaler (pMDI).
The Boehringer Ingelheim group is one of the worlds 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and almost 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2005, Boehringer Ingelheim posted net sales of 9.5 billion euro while spending almost one fifth of net sales in its largest business segment Prescription Medicines on research and development.
- Contact Information
- Judith von Gordon
- Boehringer Ingelheim GmbH
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.